277 related articles for article (PubMed ID: 25758472)
1. ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis.
Sergott RC; Bennett JL; Rieckmann P; Montalban X; Mikol D; Freudensprung U; Plitz T; van Beek J;
J Neurol Sci; 2015 Apr; 351(1-2):174-178. PubMed ID: 25758472
[TBL] [Abstract][Full Text] [Related]
2. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J;
Lancet Neurol; 2014 Apr; 13(4):353-63. PubMed ID: 24613349
[TBL] [Abstract][Full Text] [Related]
3. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.
Martinez-Lapiscina EH; Arnow S; Wilson JA; Saidha S; Preiningerova JL; Oberwahrenbrock T; Brandt AU; Pablo LE; Guerrieri S; Gonzalez I; Outteryck O; Mueller AK; Albrecht P; Chan W; Lukas S; Balk LJ; Fraser C; Frederiksen JL; Resto J; Frohman T; Cordano C; Zubizarreta I; Andorra M; Sanchez-Dalmau B; Saiz A; Bermel R; Klistorner A; Petzold A; Schippling S; Costello F; Aktas O; Vermersch P; Oreja-Guevara C; Comi G; Leocani L; Garcia-Martin E; Paul F; Havrdova E; Frohman E; Balcer LJ; Green AJ; Calabresi PA; Villoslada P;
Lancet Neurol; 2016 May; 15(6):574-84. PubMed ID: 27011339
[TBL] [Abstract][Full Text] [Related]
4. [Retinal atrophy using optical coherence tomography (OCT) in 15 patients with multiple sclerosis and comparison with healthy subjects].
Jeanjean L; Castelnovo G; Carlander B; Villain M; Mura F; Dupeyron G; Labauge P
Rev Neurol (Paris); 2008 Nov; 164(11):927-34. PubMed ID: 18808761
[TBL] [Abstract][Full Text] [Related]
5. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial.
van Vollenhoven RF; Kinnman N; Vincent E; Wax S; Bathon J
Arthritis Rheum; 2011 Jul; 63(7):1782-92. PubMed ID: 21452294
[TBL] [Abstract][Full Text] [Related]
6. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
Dall'Era M; Chakravarty E; Wallace D; Genovese M; Weisman M; Kavanaugh A; Kalunian K; Dhar P; Vincent E; Pena-Rossi C; Wofsy D
Arthritis Rheum; 2007 Dec; 56(12):4142-50. PubMed ID: 18050206
[TBL] [Abstract][Full Text] [Related]
7. Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography.
Costello F; Hodge W; Pan YI; Eggenberger E; Coupland S; Kardon RH
Mult Scler; 2008 Aug; 14(7):893-905. PubMed ID: 18573837
[TBL] [Abstract][Full Text] [Related]
8. Treatment with atacicept enhances neuronal cell death in a rat model of optic neuritis.
Kretzschmar B; Hein K; Moinfar Z; Könnecke B; Sättler MB; Hess H; Weissert R; Bähr M
J Neuroimmunol; 2014 Mar; 268(1-2):58-63. PubMed ID: 24485150
[TBL] [Abstract][Full Text] [Related]
9. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials.
Henderson AP; Altmann DR; Trip AS; Kallis C; Jones SJ; Schlottmann PG; Garway-Heath DF; Plant GT; Miller DH
Brain; 2010 Sep; 133(9):2592-602. PubMed ID: 20566483
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
van Vollenhoven RF; Wax S; Li Y; Tak PP
Arthritis Rheumatol; 2015 Nov; 67(11):2828-36. PubMed ID: 26137975
[TBL] [Abstract][Full Text] [Related]
11. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol.
Diem R; Molnar F; Beisse F; Gross N; Drüschler K; Heinrich SP; Joachimsen L; Rauer S; Pielen A; Sühs KW; Linker RA; Huchzermeyer C; Albrecht P; Hassenstein A; Aktas O; Guthoff T; Tonagel F; Kernstock C; Hartmann K; Kümpfel T; Hein K; van Oterendorp C; Grotejohann B; Ihorst G; Maurer J; Müller M; Volkmann M; Wildemann B; Platten M; Wick W; Heesen C; Schiefer U; Wolf S; Lagrèze WA
BMJ Open; 2016 Mar; 6(3):e010956. PubMed ID: 26932144
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.
Sühs KW; Hein K; Sättler MB; Görlitz A; Ciupka C; Scholz K; Käsmann-Kellner B; Papanagiotou P; Schäffler N; Restemeyer C; Bittersohl D; Hassenstein A; Seitz B; Reith W; Fassbender K; Hilgers R; Heesen C; Bähr M; Diem R
Ann Neurol; 2012 Aug; 72(2):199-210. PubMed ID: 22926853
[TBL] [Abstract][Full Text] [Related]
13. Analysis of macular and nerve fiber layer thickness in multiple sclerosis patients according to severity level and optic neuritis episodes.
Soler García A; Padilla Parrado F; Figueroa-Ortiz LC; González Gómez A; García-Ben A; García-Ben E; García-Campos JM
Neurologia; 2016; 31(6):379-88. PubMed ID: 25529178
[TBL] [Abstract][Full Text] [Related]
14. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
Raftopoulos R; Hickman SJ; Toosy A; Sharrack B; Mallik S; Paling D; Altmann DR; Yiannakas MC; Malladi P; Sheridan R; Sarrigiannis PG; Hoggard N; Koltzenburg M; Gandini Wheeler-Kingshott CA; Schmierer K; Giovannoni G; Miller DH; Kapoor R
Lancet Neurol; 2016 Mar; 15(3):259-69. PubMed ID: 26822749
[TBL] [Abstract][Full Text] [Related]
15. A prospective cohort study of vitamin D in optic neuritis recovery.
Burton JM; Eliasziw M; Trufyn J; Tung C; Carter G; Costello F
Mult Scler; 2017 Jan; 23(1):82-93. PubMed ID: 27037181
[TBL] [Abstract][Full Text] [Related]
16. Changes in oxygen saturation and the retinal nerve fibre layer in patients with optic neuritis - a pilot study.
Svrčinová T; Mareš J; Chrapek O; Šínová I; Rybariková M; Otruba P; Kaňovský P; Šín M
Acta Ophthalmol; 2018 May; 96(3):e309-e314. PubMed ID: 29090843
[TBL] [Abstract][Full Text] [Related]
17. Color-code agreement among stratus, cirrus, and spectralis optical coherence tomography in relapsing-remitting multiple sclerosis with and without prior optic neuritis.
Rebolleda G; González-López JJ; Muñoz-Negrete FJ; Oblanca N; Costa-Frossard L; Álvarez-Cermeño JC
Am J Ophthalmol; 2013 May; 155(5):890-7. PubMed ID: 23398979
[TBL] [Abstract][Full Text] [Related]
18. Reduced retinal nerve fiber layer and macular thickness in patients with multiple sclerosis with no history of optic neuritis identified by the use of spectral domain high-definition optical coherence tomography.
Fjeldstad C; Bemben M; Pardo G
J Clin Neurosci; 2011 Nov; 18(11):1469-72. PubMed ID: 21917458
[TBL] [Abstract][Full Text] [Related]
19. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations.
Zimmermann H; Freing A; Kaufhold F; Gaede G; Bohn E; Bock M; Oberwahrenbrock T; Young KL; Dörr J; Wuerfel JT; Schippling S; Paul F; Brandt AU
Mult Scler; 2013 Apr; 19(4):443-50. PubMed ID: 22936335
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin.
Shayegannejad V; Shahzamani S; Dehghani A; Dast Borhan Z; Rahimi M; Mirmohammadsadeghi A
Graefes Arch Clin Exp Ophthalmol; 2015 May; 253(5):797-801. PubMed ID: 25605544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
